Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKamada

Kamada

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
7.25 USD -0.11 ( 1.49%)
Last update at 2026-11-03T21:00:00Z
VOLUME
322336
Market Cap
466.88M
P/E
21.86

Momentum Score

…

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.04
Low
7.29
High
52 Week Price Range
6.18
Low
8.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
7.36
Dividend Yield
2.05%
Revenue TTM
191.85M
Revenue Per Share
3.28
Gross Profit TTM
78.31M
Debt / Equity
0.04
ROE
8.41%
Net Debt
-63.92M
ROCE
7.34%
Diluted EPS TTM
0.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 23.47M 13.33M 8.43M -2.26M -1.89M
Net income 20.20M 14.46M 8.28M -2.32M -2.23M
Selling general administrative 24.11M 20.41M 18.25M 12.80M 12.64M
Selling and marketing expenses 9.73M 10.43M 9.20M 15.28M 6.28M
Gross profit 76.41M 69.97M 55.49M 46.70M 30.33M
Reconciled depreciation 14.92M 13.81M 12.71M 12.15M 5.61M
Ebit 24.33M 13.99M 9.73M -1.64M -0.40M
Ebitda 39.25M 27.80M 21.20M 10.51M 5.21M
Depreciation and amortization 14.92M 13.81M 11.47M 12.15M 5.61M
Operating income 26.23M 20.05M 10.06M -1.64M -0.40M
Other operating expenses 154.23M 140.90M 132.46M 124.81M 104.34M
Interest expense 0.86M 0.66M 1.30M 0.91M 1.28M
Tax provision 3.27M -1.13M 0.14M 0.06M 0.34M
Interest income 1.92M 2.12M 0.59M 0.09M 0.29M
Net interest income 1.06M 1.46M -0.71M -0.82M -0.98M
Income tax expense 3.27M -1.13M 0.14M 0.06M 0.34M
Total revenue 180.46M 160.95M 142.52M 129.34M 103.64M
Total operating expenses 50.17M 49.92M 45.43M 42.17M 31.02M
Cost of revenue 104.05M 90.99M 87.03M 82.64M 73.31M
Total other income expense net -2.77M -6.72M -1.64M -0.62M -1.48M
Net income from continuing ops 20.20M 14.46M 8.28M -2.32M -2.23M
Net income applicable to common shares - - - -2.32M -2.23M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 378.79M 372.25M 351.97M 322.38M 318.67M
Intangible assets 96.12M 101.86M 109.64M 116.70M 153.59M
Other current assets 3.62M 3.90M 4.37M 3.88M 8.87M
Total liab 109.66M 112.79M 109.97M 146.36M 141.84M
Total stockholder equity 269.13M 259.46M 242.00M 176.02M 176.82M
Other current liab 22.04M 19.85M 23.06M 37.29M 25.13M
Common stock 15.08M 15.03M 14.90M 11.73M 11.72M
Capital stock 15.08M 15.03M 15.02M 11.73M 11.72M
Retained earnings -17.08M -25.74M -39.87M -48.48M -46.16M
Other liab - - - 55.51M 67.22M
Good will 30.32M 30.31M 30.06M 30.31M 0.07M
Other assets - - 0.00M 7.64M 5.63M
Cash 75.48M 78.44M 55.18M 34.26M 18.59M
Total current liabilities 47.40M 49.39M 49.18M 75.70M 54.06M
Current deferred revenue - 0.17M 0.15M 0.04M 0.04M
Net debt -63.92M -67.37M -46.43M -13.66M 5.76M
Short term debt 2.12M 1.63M 1.37M 5.46M 3.79M
Short long term debt - - - 4.44M 20.62M
Short long term debt total 11.56M 11.06M 8.75M 20.60M 24.35M
Other stockholder equity 268.34M 273.25M 263.65M 216.00M 214.85M
Property plant equipment - - - 28.73M 29.40M
Total current assets 193.12M 184.35M 168.56M 139.00M 130.04M
Net tangible assets - - - 29.01M 23.23M
Short term investments - - - - 0.00M
Net receivables 29.05M 23.20M 21.26M 35.96M 44.03M
Long term debt - - - 12.96M 17.41M
Inventory 84.96M 78.82M 87.75M 68.78M 67.42M
Accounts payable 23.25M 27.73M 24.60M 32.92M 25.10M
Accumulated other comprehensive income 2.78M -3.08M 3.32M -3.23M -3.58M
Non currrent assets other 1.42M 9.38M 0.51M 7.58M 5.56M
Non current assets total 185.67M 187.91M 183.41M 183.37M 188.62M
Capital lease obligations 11.56M 11.06M 8.82M 3.19M 4.31M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -10.74M -5.84M -3.78M 39.08M
Change to liabilities - - - 7.04M 9.73M
Total cashflows from investing activities -10.65M -10.74M -5.84M -3.78M -61.05M
Net borrowings -0.97M -1.25M -18.26M -3.73M 18.57M
Total cash from financing activities -19.86M -13.91M 22.68M -9.34M 18.59M
Change to operating activities - - - -1.63M -8.91M
Net income 21.86M 14.46M 8.28M -2.32M -2.23M
Change in cash -2.95M 22.79M 21.38M 15.67M -51.34M
Begin period cash flow 78.43M 55.64M 34.26M 18.59M 70.20M
End period cash flow 75.48M 78.44M 55.64M 34.26M 18.86M
Total cash from operating activities 27.59M 47.59M 4.32M 28.59M -8.82M
Issuance of capital stock 0.00M 0.00M 58.23M 0.00M 0.00M
Depreciation 16.15M 13.81M 12.71M 12.15M 5.61M
Other cashflows from investing activities - 0.00M 0.01M - -
Dividends paid 12.49M 0.00M 0.00M - -
Change to inventory -6.63M 9.66M -19.69M -1.36M -2.37M
Change to account receivables -5.92M -0.91M 9.50M 7.60M -12.86M
Other cashflows from financing activities -6.45M -12.66M -17.30M 0.01M 20.02M
Change to netincome - - - 7.10M 2.21M
Capital expenditures 10.66M 10.74M 5.85M 3.78M 3.73M
Change in working capital -19.14M 11.41M -18.20M 11.65M -14.41M
Stock based compensation 0.84M 0.87M 1.31M 1.15M 0.53M
Other non cash items 8.72M 8.16M 0.06M 5.89M 1.34M
Free cash flow 16.93M 36.85M -1.53M 24.80M -12.55M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KMDA
Kamada		 -0.11
1.49%		 7.25 21.86 15.65 2.43 1.78 2.17 9.67
MKKGY
Merck KGaA ADR		 -0.50
1.48%		 33.21 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.26
0.75%		 167.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.75 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -0.91
2.17%		 41.09 - 10.66 0.01 1.16 2.94 23.11

Profile*

Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

2 Holzman Street, Rehovot, Israel, 7670402

972 8 940 6472

https://www.kamada.com

462

Name Title Year Born
Mr. Amir London Chief Exec. Officer 1969
Mr. Chaime Orlev Chief Financial Officer 1970
Mr. Eran Nir Chief Operating Officer 1973
Ms. Yifat Philip Esq. VP of Legal, Gen. Counsel & Corp. Sec. 1977
Mr. David Tsur Co-Founder & Deputy Chairman 1950
Ms. Hanni Neheman VP of Marketing & Sales 1970
Ms. Ariella Raban VP of HR 1976
Mr. Jon R. Knight VP of US Commercial Operations NA
Mr. Amir London Chief Executive Officer 1969
Mr. Jon R. Knight Vice President of US Commercial Operations 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…